EGFR and neoplasm: For five representative cases who received combination therapy (pemetrexed administered one week prior to aumolertinib) as neoadjuvant therapy, the significant tumor regressions were observed in patients harboring EGFR mutant after 2–3 cycle treatment (Table 2), independent of the different concomitant mutations.